A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease
Corresponding Author
Elise E. Drouin
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Massachusetts General Hospital, CNY 149/8301, 55 Fruit Street, Boston, MA 02114Search for more papers by this authorRobert J. Seward
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Search for more papers by this authorKlemen Strle
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorGail McHugh
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorKianoosh Katchar
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorDiana Londoño
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorChunxiang Yao
Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorCatherine E. Costello
Boston University School of Medicine, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Search for more papers by this authorAllen C. Steere
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Dr. Steere has received consulting fees, speaking fees, and/or honoraria from Merck and Alere (less than $10,000 each).
Search for more papers by this authorCorresponding Author
Elise E. Drouin
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Massachusetts General Hospital, CNY 149/8301, 55 Fruit Street, Boston, MA 02114Search for more papers by this authorRobert J. Seward
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Search for more papers by this authorKlemen Strle
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorGail McHugh
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorKianoosh Katchar
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorDiana Londoño
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorChunxiang Yao
Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorCatherine E. Costello
Boston University School of Medicine, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Search for more papers by this authorAllen C. Steere
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Drs. Drouin, Seward, Costello, and Steere have a patent application pending for endothelial cell growth factor antibody testing.
Dr. Steere has received consulting fees, speaking fees, and/or honoraria from Merck and Alere (less than $10,000 each).
Search for more papers by this authorDr. Steere has received consulting fees, speaking fees, and/or honoraria from Merck and Alere (less than $10,000 each).
Abstract
Objective
Autoantigen presentation by HLA–DR molecules is thought to be a central component of many autoimmune diseases, but identifying disease-relevant autoantigens has been a difficult challenge. In this study we aimed to identify autoantigens in patients with antibiotic-refractory Lyme arthritis, in which infection-induced autoimmunity is thought to play an important role.
Methods
Using tandem mass spectrometry, naturally presented HLA–DR self peptides from a patient's synovium were identified, synthesized, and reacted with his peripheral blood mononuclear cells (PBMCs). Immunoreactive peptides and their source proteins were then tested for T and B cell responses using large numbers of patient cells or sera.
Results
Of 120 HLA–DR–presented self peptides identified from one patient, one peptide derived from endothelial cell growth factor (ECGF) caused his PBMCs to proliferate. T and B cell responses to ECGF occurred systemically in ∼10–30% of patients with early or late manifestations of Lyme disease, primarily in those with refractory arthritis–associated HLA–DR alleles, such as DRB1*0101 and 0401. Compared with patients with antibiotic-responsive arthritis, those with antibiotic-refractory arthritis had significantly higher concentrations of ECGF in synovial fluid (P < 0.0001) and more often had ECGF antibody reactivity. Among non–antibiotic-treated historical patients who developed arthritis, 26% had ECGF reactivity, which often developed before the onset of arthritis and was associated with significantly longer courses of arthritis.
Conclusion
T and B cell responses to ECGF occur in a subset of patients with Lyme disease, particularly in those with antibiotic-refractory arthritis, providing the first direct evidence of autoimmune T and B cell responses in this illness.
REFERENCES
- 1 Sonderstrup G, McDevitt HO. DR, DQ, and you: MHC alleles and autoimmunity. J Clin Invest 2001; 107: 795–6.
- 2 Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011; 365: 1612–23.
- 3 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–19.
- 4 Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–33.
- 5 Steere AC. Lyme disease. N Engl J Med 2001; 345: 115–25.
- 6 Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725–31.
- 7 Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH III, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878–88.
- 8 Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis [review]. Arthritis Rheum 2006; 54: 3079–86.
- 9 Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004; 4: 143–52.
- 10 Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 2012; 122: 2652–60.
- 11 Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 2011; 63: 2238–47.
- 12 Kannian P, Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Decline in the frequencies of Borrelia burgdorferi OspA161-175-specific T cells after antibiotic therapy in HLA-DRB1*0401-positive patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis. J Immunol 2007; 179: 6336–42.
- 13 Kannian P, McHugh G, Johnson BJ, Bacon RM, Glickstein LJ, Steere AC. Antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive, or non–antibiotic-treated Lyme arthritis. Arthritis Rheum 2007; 56: 4216–25.
- 14 Shin JJ, Glickstein L, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory Lyme arthritis. Arthritis Rheum 2007; 56: 1325–35.
- 15 Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006; 203: 961–71.
- 16 Steere AC, Duray PH, Butcher EC. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis: comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988; 31: 487–95.
- 17 Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703–6.
- 18 Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis. Mol Immunol 2008; 45 : 180–9.
- 19 Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011; 52 S259–65.
- 20 Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function–associated antigen 1 peptides to HLA–DR molecules associated with antibiotic treatment–resistant Lyme arthritis. Arthritis Rheum 2003; 48: 534–40.
- 21 Ghosh S, Seward R, Costello CE, Stollar BD, Huber BT. Autoantibodies from synovial lesions in chronic, antibiotic treatment-resistant Lyme arthritis bind cytokeratin-10. J Immunol 2006; 177: 2486–94.
- 22 Martin R, Ortlauf J, Sticht-Groh V, Bogdahn U, Goldmann SF, Mertens HG. Borrelia burgdorferi–specific and autoreactive T-cell lines from cerebrospinal fluid in Lyme radiculomyelitis. Ann Neurol 1988; 24: 509–16.
- 23 Kuenzle S, von Budingen HC, Meier M, Harrer MD, Urich E, Becher B, et al. Pathogen specificity and autoimmunity are distinct features of antigen-driven immune responses in neuroborreliosis. Infect Immun 2007; 75: 3842–7.
- 24 Lunemann JD, Gelderblom H, Sospedra M, Quandt JA, Pinilla C, Marques A, et al. Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early Lyme encephalitis. Infect Immun 2007; 75: 243–51.
- 25 Chandra A, Wormser GP, Klempner MS, Trevino RP, Crow MK, Latov N, et al. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun 2010; 24: 1018–24.
- 26 Wharton M, Chorba TL, Vogt RL, Morse DL, Buehler JW. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39: 1–43.
- 27 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–81.
- 28 Seward RJ, Drouin EE, Steere AC, Costello CE. Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis. Mol Cell Proteomics 2011; 10: M110.002477.
- 29 Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol 2008; 45: 2323–32.
- 30 Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27–47.
- 31 Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557–62.
- 32 Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994; 37: 662–72.
- 33 Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555–61.
- 34 Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008; 4: e1000048.
- 35 Gordon RD, Young JA, Rayner S, Luke RW, Crowther ML, Wordsworth P, et al. Purification and characterization of endogenous peptides extracted from HLA-DR isolated from the spleen of a patient with rheumatoid arthritis. Eur J Immunol 1995; 25: 1473–6.
- 36 Muixi L, Carrascal M, Alvarez I, Daura X, Marti M, Armengol MP, et al. Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands. J Immunol 2008; 181: 795–807.
- 37 Oshitani N, Hato F, Kitagawa S, Maeda K, Higuchi K, Matsumoto T, et al. Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease. Int J Mol Med 2003; 11: 99–104.
- 38 Wahlstrom J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanovic S, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest 2007; 117: 3576–82.
- 39 Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, et al. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol Cell Proteomics 2009; 8: 2090–101.
- 40 Barbour AG, Jasinskas A, Kayala MA, Davies DH, Steere AC, Baldi P, et al. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun 2008; 76: 3374–89.
- 41 Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH, Benach JL. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997; 89: 1111–9.
- 42 Hallstrom T, Haupt K, Kraiczy P, Hortschansky P, Wallich R, Skerka C, et al. Complement regulator-acquiring surface protein 1 of Borrelia burgdorferi binds to human bone morphogenic protein 2, several extracellular matrix proteins, and plasminogen. J Infect Dis 2010; 202: 490–8.
- 43 Strle K, Jones KL, Drouin EE, Li X, Steere AC. Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am J Pathol 2011; 178: 2726–39.
- 44 Jones KL, McHugh GA, Glickstein LJ, Steere AC. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: high frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum 2009; 60: 2174–82.
- 45 Strle K, Shin JJ, Glickstein LJ, Steere AC. Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum 2012; 64: 1497–507.
- 46 Van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, et al. Proinflammatory mediator–induced reversal of CD4+,CD25+ regulatory T cell–mediated suppression in rheumatoid arthritis. Arthritis Rheum 2007; 56: 732–42.
- 47 Herrath J, Muller M, Amoudruz P, Janson P, Michaelsson J, Larsson PT, et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol 2011; 41: 2279–90.
- 48 Shen S, Shin JJ, Strle K, McHugh G, Li X, Glickstein LJ, et al. Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Arthritis Rheum 2010; 62: 2127–37.
- 49 Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154–63.
